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Interaction of Morphine and Selective Serotonin Receptor 
Inhibitors in Rats Experiencing Inflammatory Pain
Citalopram and paroxetine are selective serotonin reuptake inhibitors and also have 
antinociceptive effects. We investigated the antiallodynic and antihyperalgesic effects of 
intrathecally administered morphine, citalopram, paroxetine, and combinations thereof, 
in a rat model in which peripheral inflammation was induced by complete Freund’s 
adjuvant (CFA). Drugs were intrathecally administered via direct lumbar puncture. 
Mechanical allodynia was measured using a Dynamic Plantar Aesthesiometer. Thermal 
hyperalgesia and cold allodynia were determined by measuring latency of paw withdrawal 
in response to radiant heat and cold water. Behavioral tests were run before and 15, 30, 
45, and 60 min after intrathecal injection. Intraplantar injection of CFA produced 
mechanical allodynia, thermal hyperalgesia, and cold allodynia. Intrathecally administered 
morphine (0.3 or 1 μg) had antiallodynic or antihyperalgesic effects (24.0%-71.9% 
elevation). The effects of morphine were significantly increased when a combination of 
citalopram (100 μg) and paroxetine (100 μg) was added (35.2%-95.1% elevation). This rise 
was reversed by naloxone and methysergide. The effects of citalopram and paroxetine were 
also reversed by naloxone and methysergide. We suggest that the mu opioid receptor and 
serotonin receptors play major roles in production of the antiallodynic and antihyperalgesic 
effects of morphine, citalopram, paroxetine, and combinations thereof, in animals 
experiencing inflammatory pain.
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ORIGINAL ARTICLE
Anesthesiology & Pain
INTRODUCTION
Antidepressants are psychiatric medications used to treat de-
pression and anxiety disorders (1). However, antidepressants 
also have antinociceptive and analgesic effects and are widely 
prescribed in the treatment of chronic pain (2, 3). Antidepres-
sants include the classic tricyclic drugs, nonselective norepi-
nephrine/serotonin reuptake inhibitors (amitriptyline, imipra-
mine, clomipramine, and venlafaxine), selective norepineph-
rine reuptake inhibitors (desipramine and nortriptyline), and 
selective serotonin reuptake inhibitors (SSRIs; citalopram, par-
oxetine, and fluoxetine). As SSRIs have more tolerable auto-
nomic side-effects than do classical tricyclic antidepressants, 
the former drugs have recently become more frequently used 
for treatment of pain (4, 5).
  The mechanisms responsible for the antinociceptive effects 
of antidepressants are not entirely clear. Antidepressants, such 
as the tricyclic antidepressants and SSRIs, interfere with reup-
take of monoamines, including noradrenaline and serotonin, 
at the neuronal terminal (6). Serotonergic and noradrenergic 
pathways descending from the rostral ventral medulla to the 
spinal cord are known to modulate ascending spinal pain trans-
mission (7, 8) at synapses between dorsal horn neurons and 
primary afferent fibers (9). Therefore, we hypothesized that the 
antinociceptive effects of SSRIs might be caused, at least in part, 
by inhibition of reuptake of noradrenaline and serotonin.
  Inflammatory pain in peripheral tissues is a common clinical 
symptom and usually induces chronic allodynia and/or hyper-
algesia. Intrathecally administered morphine caused thermal 
antihyperalgesia in a rat model of peripheral inflammation in-
duced by injection of complete Freund’s adjuvant (CFA) into 
the plantar surface of the paw (10). However, no report on the 
antinociceptive effect of intrathecally administered SSRIs in a 
rat model of peripheral inflammation induced by CFA has ap-
peared.
  Therefore, in the present study we investigated the antinoci-
ceptive effect of intrathecally administered morphine or SSRIs 
(paroxetine and citalopram), and additionally examined the 
antinociceptive interaction between intrathecally administered 
morphine and SSRIs in a rat model of peripheral inflammation 
induced by injection of CFA into the plantar surface of the paw. 
We also explored whether either methysergide (a nonselective 
5-HT1, 5-HT2, and 5-HT7 serotonin receptor antagonist) or nal-
oxone (a nonselective antagonist of opioid receptors) alone re-Lee B-S, et al.  •  Interaction of Morphine and SSRIs
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Fig. 1. Experimental design: four sets of experiments were conducted. i.t., intrathecal 
injection.
versed the antiallodynic and antihyperalgesic effects induced 
by a combination of morphine and SSRIs.
MATERIALS AND METHODS
Our study protocol was approved by the Animal Use and Care 
Committee of the Asan Institute for Life Science. Experiments 
were conducted on male Sprague-Dawley rats weighing 200-
250 g, housed individually in a temperature-controlled vivari-
um and allowed to acclimate for 3 days under a 12 hr/12 hr 
light/dark cycle. 
  Inflammatory pain was induced by injection of 100 μL CFA 
into the plantar surface of the left hindpaw of rats anesthetized 
with sevoflurane. Four sets of experiments were conducted and 
8 rats were included per group (Fig. 1). Experiment 1 was de-
signed to test the antinociceptive abilities of intrathecally ad-
ministered morphine (0.3 and 1 μg), citalopram (100 μg), and 
paroxetine (100 μg) alone. In the control group, normal saline 
10 μL was intrathecally injected. Experiment 2 explored the an-
tinociceptive interaction of intrathecally co-administered mor-
phine (0.3 and 1 μg) plus citalopram (100 μg), and morphine (0.3 
and 1 μg) plus paroxetine (100 μg). Experiment 3 was designed 
to investigate the mechanism of antinociceptive interaction be-
tween a combination of morphine plus citalopram or parox-
etine. Methysergide (100 μg) or naloxone (20 μg) was intrathe-
cally injected 10 min before co-administration of morphine (0.3 
and 1 μg) plus citalopram (100 μg) or paroxetine (100 μg). Ex-
periment 4 explored the possibility of the existence of a cross-
reaction between morphine and methysergide, or citalopram/
paroxetine and naloxone. The antinociceptive interaction of 
both drugs was investigated after intrathecal co-administration 
of morphine (0.3 and 1 μg) and methysergide (100 μg), or cital-
opram (100 μg)/paroxetine (100 μg) and naloxone (20 μg).
  The doses of drugs were determined on the basis of our pre-
vious study (11). We investigated the antiallodynic interaction 
between intrathecally administered morphine (0.3 or 1 μg) and 
citalopram 300 μg or paroxetine 300 μg in a rat model of neuro-
pathic pain (spinal nerve ligation). The antiallodynic effect of 
morphine was increased with co-administration of citalopram 
or paroxetine and the increased effect was reversed by nalox-
one and methysergide.
  Drugs were administered in 10 μL volumes by direct lumbar 
puncture between the L5 and L6 vertebrae (12). Briefly, rats 
were anesthetized with sevoflurane in oxygen via nose cone. 
The lumbar region was shaved, prepared with Betadine solu-
tion, and the intervertebral spaces widened by placing the ani-
mal on a 50 mL syringe tube. Animals were then injected at the 
L5-6 interspace using a 0.5-inch 30-gauge needle (Becton-Dick-
inson, Utah, USA) connected to a Hamilton syringe (Microliter
TM 
#702, Hamilton Co., Nevada, USA). The Hamilton syringe was 
filled with test drug 10-20 μL. The needle plunger was then 
slowly lowered over a 30-sec interval in a volume of just 10 μL 
and the needle was immediately pulled out. Correct subarach-
noid positioning of the tip of the needle was verified by a tail- or 
paw-flick test (12). Animals then recovered in their home cage 
before behavioral testing. Experimenters were blind to drug 
treatment groups, and all drug and pain treatment groups were 
tested in randomized order. Behavioral studies were performed 
3-4 days after CFA injection. 
  Mechanical allodynia, expressed in grams (g), was measured 
using a Dynamic Plantar Aesthesiometer (Ugo Basile, Varese,   
Italy). Rats were placed on a wire-mesh floor in individual plas-
tic boxes and were allowed to acclimate for 30 min prior to the 
first test. Increasing force was applied, using a metal rod 2 mm 
in diameter, to the plantar side of the left paw. The force was in-
creased from 0 g to 50 g over 10 sec. When a rat withdrew the 
paw, the mechanical stimulus stopped automatically; the time 
Experimental design (n=8 in each group)
Experiment 1: antinociceptive effect of each drug alone
morphine 0.3 µg i.t.  ①
morphine 1 µg i.t.  ②
citalopram 100 µg i.t.  ③
paroxetine 100 µg i.t.  ④
methysergide 100 µg i.t.  ⑤
naloxone 20 µg i.t.  ⑥
saline 10 µL i.t.  ⑦
Experiment 2: antinociceptive interaction of both drugs
morphine 0.3 µg  + 
citalopram 100 µg i.t.  ①
  paroxetine 100 µg i.t.  ②
morphine 1 µg   
citalopram 100 µg i.t.  ③
  paroxetine 100 µg i.t.  ④
Experiment 3: antagonist pretreatment
    citalopram 100 µg i.t.  ①
    paroxetine 100 µg i.t.  ②
    citalopram 100 µg i.t.   ③
    paroxetine 100 µg i.t.   ④
    citalopram 100 µg i.t.  ⑤
    paroxetine 100 µg i.t.  ⑥
    citalopram 100 µg i.t.   ⑦
    paroxetine 100 µg i.t.   ⑧
Experiment 4: cross-reaction
methysergide 100 µg  
+ pretreatment
naloxone 20 µg  
pretreatment
morphine 0.3 µg +
morphine 0.3 µg +
morphine 1 µg 
morphine 1 µg 
methysergide 100 µg  
+ pretreatment
morphine 0.3 µg i.t.
morphine 1 µg i.t.
naloxone 20 µg  
pretreatment
citalopram 100 µg i.t.
paroxetine 100 µg i.t.
①
②
③
④
+
+
+
+
+
+
+
+
+
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(sec) to, and the force (weight in g; 0.5 g sensitivity) applied at, 
the time of paw withdrawal were recorded. A maximal cut-off 
value of 50 g was set to prevent tissue damage. Paw withdrawal 
responses were repeated four times at 10 sec intervals. Paw with-
drawal threshold and time to withdrawal are shown as the aver-
ages of the four measurements.
  Thermal hyperalgesia was assessed by measuring the latency 
of paw withdrawal in response to a radiant heat source (13). Rats 
were housed individually in Plexiglas chambers on an elevated 
glass platform, under which a radiant heat source (Ugo Basile) 
was applied to the plantar surface of the hind paw through a 
glass plate maintained at 30°C. The heat source was turned off 
when the rat lifted the foot, and the time from onset of radiant 
heat application to withdrawal of the hindpaw was noted and 
defined as paw withdrawal latency (PWL). The heat was main-
tained at constant intensity, and resulted in a stable PWL of ap-
proximately 10-12 sec in normal rats. A 20 sec cutoff was set to 
prevent tissue damage. PWL was measured three times at 5 min 
intervals and average values were calculated.
  Cold allodynia was determined by immersion of the hind 
paw into a water bath containing cold (4°C) water, and latency 
to paw withdrawal was measured using a digital timer accurate 
to 1/100 sec. A cut off time of 20 sec was set. Paw withdrawal la-
tency to cold stimulation was measured three times, at 5 min 
intervals, and the data were averaged (14). Measurements for 
behavioral tests were taken before and 15, 30, 45, and 60 min 
after intrathecal dosing. 
  Locomotor functional changes were evaluated by rotarod 
testing (Acceler Rota-Rod for Rats 7750; Ugo Basile). Rats were 
acclimated to revolving drums, and habituated to handling, to 
ameliorate stress during testing. Before the day of drug tests, 
rats were given three training trials on revolving drums of axis 
diameter 6.0 cm, with a corrugated surface, over 2 days. Rats 
were placed on the drum rotating at the lowest possible speed 
of 4 rpm and the speed was increased as the rate of 0.12 rpm/
sec, to a maximum of 40 rpm. Rats able to remain on the revolv-
ing drum for a minimum of 120 sec were selected for drug test-
ing. The mean of three training runs served to control perfor-
mance time. Rotarod performance was measured 30 min and 
60 min after intrathecal injection. Each test was performed three 
times at 5 min intervals, and mean values were calculated.
  Morphine sulfate (Lot No. M8777), CFA (F5881), citalopram 
(C7861), paroxetine (P1372), naloxone (N7758), methysergide 
(M137), and dimethyl sulfoxide (DMSO, minimum 99.5% [v/v], 
D5879) were purchased from Sigma-Aldrich (St. Louis, MO, 
USA). Paroxetine and methysergide were dissolved in DMSO 
and diluted with 0.9% (w/v) sodium chloride. All other drugs 
were dissolved in 0.9% (w/v) sodium chloride.
  Data are expressed as means ± SDs. Statistical comparisons 
of differences between agonistic effects, drug combinations, 
and antagonistic effects were performed using one-way analy-
sis of variance (ANOVA) followed by Tukey’s multiple compari-
sons test. Repeated-measures ANOVA were performed within 
groups to explore within-subject factors, followed by Tukey’s 
multiple comparisons test. Statistical evaluation was performed 
with SigmaPlot
® software version 11 (Systat Software Inc., San 
Jose, CA, USA). A P value < 0.05 was considered statistically sig-
nificant.
RESULTS
Total 184 rats were used in the present experiment. Intraplantar 
injection of CFA produced classical signs of acute inflammation 
including edema, redness, and heat. Mechanical allodynia, ther-
mal hyperalgesia, and cold allodynia peaked 1-4 days after CFA 
injection and persisted for more than 7 days (Fig. 2). The pre 
CFA injection threshold of mechanical allodynia (45.8 ± 3.8 g) 
and the pre CFA injection latency of thermal hyperalgesia (9.8 ±  
1.0 sec) and cold allodynia (9.8 ± 1.0 sec) fell significantly, to 
20.9 ± 5.4 g, 4.2 ± 0.8 sec, and 4.7 ± 0.9 sec, respectively (Fig. 2).
  In experiment 1, intrathecally injected paroxetine, morphine, 
and drug combinations (morphine plus citalopram or parox-
etine) had antiallodynic and antihyperalgesic effects. However, 
citalopram alone did not produce any antinociceptive effect. 
The maximal effects occurred within 15-30 min and next grad-
ually decreased over time for all drug combinations. Dose de-
pendent increases in both the magnitude and duration of ef-
fects were evident (Tables 1, 2, and 3).
  In experiment 1 and 2, the threshold of mechanical allodynia 
for paroxetine, morphine 0.3 μg and 1 μg were significantly in-
creased to 30.5 ± 2.7 g, 32.0 ± 5.9 g and 41.3 ± 4.8 g, respective-
ly. Upon co-administration of citalopram 100 μg, the allodynic 
threshold for morphine (0.3 and 1 μg) significantly increased to 
38.6 ± 3.7 g and 48.0 ± 1.4 g compared to the morphine-alone 
group. Upon co-administration of paroxetine 100 μg, the allo-
dynic thresholds for morphine (0.3 and 1 μg) were significantly 
increased to 42.4 ± 3.1 g and 48.5 ± 1.5 g, compared to the mor-
phine-alone group (Table 1). The latency of thermal hyperalge-
sia for paroxetine, morphine 0.3 μg and 1 μg were significantly 
increased to 7.2 ± 0.5 g, 8.1 ± 1.0 g and 12.1 ± 1.1 g, respectively. 
Upon co-administration of citalopram 100 μg, the hyperalgesic 
latency for morphine (0.3 and 1 μg) was significantly increased 
to 10.5 ± 0.9 sec and 16.0 ± 1.0 sec compared with the morphine-
alone group. Upon co-administration of paroxetine 100 μg, the 
hyperalgesic latency for morphine (0.3 and 1 μg) was signifi-
cantly increased to 13.4 ± 0.9 sec and 19.2 ± 0.5 sec compared 
with the morphine-alone group (Table 2). The latency of cold 
allodynia for paroxetine, morphine 0.3 μg and 1 μg were signifi-
cantly increased to 8.8 ± 0.7 g, 8.9 ± 0.8 g and 13.2 ± 1.1 g, re-
spectively. Upon co-administration of citalopram 100 μg, the 
allodynic latency for morphine (0.3 and 1 μg) was significantly 
increased to 10.6 ± 1.1 sec and 17.0 ± 0.8 sec compared with Lee B-S, et al.  •  Interaction of Morphine and SSRIs
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Fig. 2. Time course of mechanical allodynia, thermal hyperalgesia, and cold allodynia 
after Complete Freund’s Adjuvant (CFA) injection. *P < 0.05 vs naïve rats.
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Table 1. Time course of mechanical antiallodynic effects after intrathecal injection of 
morphine, citalopram, paroxetine, and combinations
Group Baseline 15 min 30 min 45 min 60 min
Control 19.0 ± 3.0 18.3 ± 2.4 20.3 ± 1.7 18.0 ± 2.1 18.6 ± 1.5
C 20.3 ± 2.7 23.2 ± 3.8 21.5 ± 2.8 20.5 ± 5.3 20.0 ± 1.3
P 20.6 ± 2.1 30.5 ± 2.7 26.8 ± 2.0 23.5 ± 2.9 22.1 ± 2.3
m 18.4 ± 2.1 32.0 ± 5.9 25.7 ± 4.3 20.6 ± 3.4 18.9 ± 2.1
mC 20.2 ± 3.0 38.6 ± 3.7* 33.7 ± 3.7* 25.4 ± 2.7* 25.0 ± 2.6*
mP 21.2 ± 2.1 42.4 ± 3.1* 37.7 ± 3.1* 32.4 ± 1.9* 27.0 ± 1.8*
M 19.0 ± 2.6 41.3 ± 4.8 39.3 ± 3.5 33.0 ± 3.6 29.3 ± 4.2
MC 20.5 ± 2.4 48.0 ± 1.4
† 45.9 ± 1.6
† 42.4 ± 2.2
† 36.4 ± 2.5
†
MP 19.6 ± 1.5 48.5 ± 1.5
† 47.2 ± 1.3
† 44.6 ± 2.1
† 42.2 ± 3.6
†
NMC 21.0 ± 2.5 28.8 ± 2.2
‡ 25.3 ± 2.8
‡ 26.7 ± 2.4
‡ 23.1 ± 2.1
‡
TMC 20.2 ± 1.9 34.2 ± 3.8
‡ 33.3 ± 2.7
‡ 27.9 ± 2.5
‡ 24.2 ± 2.5
‡
NMP 20.7 ± 2.3 30.7 ± 2.7
§ 29.4 ± 3.5
§ 25.0 ± 3.0
§ 25.5 ± 1.8
§
TMP 20.4 ± 1.5 34.3 ± 4.8
§ 30.3 ± 3.5
§ 32.0 ± 3.6
§ 25.4 ± 4.2
§
TM 19.9 ± 2.7 29.0 ± 2.9
† 25.5 ± 2.8
† 21.5 ± 5.5
† 20.0 ± 1.3
†
NC 20.5 ± 2.4 21.9 ± 2.3 20.1 ± 2.9 20.8 ± 2.9 20.6 ± 2.5
NP 21.7 ± 2.2 24.2 ± 2.8
II 22.3 ± 2.4
II 21.2 ± 2.1 21.5 ± 2.0
Data are means ± SDs from eight rats per group. C, citalopram 100 µg; P, paroxetine 
100 µg; m, morphine 0.3 µg; M, morphine 1 µg; T, methysergide 100 µg pretreat-
ment; N, naloxone 20 µg pretreatment; mC, mP, MC, MP, TM, NC, and NP, the antial-
lodynic interaction of both drugs; NMC and NMP, pretreatment of naloxone 20 µg be-
fore co-administration of both drugs; TMC and TMP, pretreatment of methysergide 
100 µg before co-administration of both drugs. * < 0.05 vs m; 
† < 0.05 vs M; 
‡ < 0.05 
vs MC; 
§ < 0.05 vs MP; 
II < 0.05 vs P.
Table 2. Time course of thermal antihyperalgesic effects after intrathecal injection of 
morphine, citalopram, paroxetine, and combinations
Group Baseline 15 min 30 min 45 min 60 min
Control 4.2 ± 0.9 4.3 ± 0.6 4.4 ± 0.9 3.8 ± 0.9 4.0 ± 0.6
C 4.4 ± 0.8 5.6 ± 1.2 4.7 ± 0.6 4.4 ± 0.4 3.9 ± 0.3
P 4.7 ± 1.0 7.2 ± 0.5 7.0 ± 1.0 5.5 ± 0.3 4.2 ± 0.5
m 4.1 ± 0.7 8.1 ± 1.0 7.4 ± 0.7 5.9 ± 1.0 5.1 ± 0.8
mC 4.3 ± 0.7 10.5 ± 0.9* 9.5 ± 0.7* 7.7 ± 0.6* 7.2 ± 0.9*
mP 4.6 ± 0.6 13.4 ± 0.9* 12.1 ± 0.8* 9.4 ± 0.8* 7.7 ± 0.9*
M 4.3 ± 0.4 12.1 ± 1.1 11.8 ± 0.7 10.4 ± 0.8 8.9 ± 0.8
MC 4.5 ± 0.6 16.0 ± 1.0
† 15.7 ± 0.8
† 13.1 ± 1.1
† 11.6 ± 1.0
†
MP 4.5 ± 0.6 19.2 ± 0.5
† 18.0 ± 0.7
† 16.4 ± 1.1
† 15.1 ± 1.0
†
NMC 4.3 ± 0.6 7.6 ± 0.6
‡ 7.3 ± 0.7
‡ 6.4 ± 0.8
‡ 4.6 ± 0.8
‡
TMC 4.3 ± 0.7 9.9 ± 0.8
‡ 8.8 ± 0.8
‡ 8.0 ± 0.7
‡ 6.5 ± 0.7
‡
NMP 4.2 ± 0.5 8.1 ± 0.9
§ 6.6 ± 0.7
§ 6.8 ± 0.7
§ 5.6 ± 0.8
§
TMP 4.2 ± 0.7 9.9 ± 0.9
§ 10.9 ± 0.8
§ 8.5 ± 0.8
§ 7.0 ± 0.6
§
TM 4.3 ± 0.3 6.6 ± 1.0
† 6.1 ± 0.9
† 5.0 ± 0.4
† 4.5 ± 0.4
†
NC 4.2 ± 0.3 4.2 ± 0.3
ll 4.1 ± 0.3 4.1 ± 0.3 4.0 ± 0.2
NP 4.7 ± 0.3 5.7 ± 0.5
¶ 5.3 ± 0.5 5.2 ± 0.4 4.5 ± 0.4
Data are means ± SDs from eight rats per group. C, citalopram 100 µg; P, parox-
etine 100 µg; m, morphine 0.3 µg; M, morphine 1 µg; T, methysergide 100 µg pre-
treatment; N, naloxone 20 µg pretreatment; mC, mP, MC, MP, TM, NC, and NP, the 
antihyperalgesic interaction of both drugs; NMC and NMP, pretreatment of naloxone 
20 µg before co-administration of both drugs; TMC and TMP, pretreatment of methy-
sergide 100 µg before co-administration of both drugs. * < 0.05 vs m; 
† < 0.05 vs M; 
‡ < 0.05 vs MC; 
§ < 0.05 vs MP; 
II < 0.05 vs C; 
¶ < 0.05 vs P.
the morphine-alone group. Upon co-administration of parox-
etine 100 μg, the allodynic latency for morphine (0.3 and 1 μg) 
significantly increased to 12.7 ± 0.7 sec and 18.4 ± 0.7 sec com-
pared with the morphine-alone group (Table 3).
  In experiment 3, the increased antinociceptive effects of drug 
combinations (morphine 1 μg and citalopram 100 μg or parox-
etine 100 μg) were significantly reversed upon pretreatment of 
naloxone 20 μg or methysergide 100 μg (Tables 1, 2, and 3). The 
threshold of mechanical allodynia for a combination of mor-
phine 1 μg and citalopram 100 μg significantly decreased from 
48.0 ± 1.4 g to 28.8 ± 2.2 g and 34.2 ± 3.8 g upon pretreatment of 
naloxone or methysergide, respectively (Table 1). The threshold 
of mechanical allodynia for a combination of morphine 1 μg 
and paroxetine 100 μg decreased significantly from 48.5 ± 1.5 g 
to 30.7 ± 2.7 g and 34.3 ± 4.8 g upon pretreatment of naloxone Lee B-S, et al.  •  Interaction of Morphine and SSRIs
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or methysergide, respectively (Table 1). The latency of thermal 
hyperalgesia upon administration of a combination of morphine 
1 μg and citalopram 100 μg was decreased significantly from 
16.0 ± 1.0 sec to 7.6 ± 0.6 sec and 9.9 ± 0.8 sec by naloxone and 
methysergide, respectively (Table 2). The threshold of mechani-
cal allodynia for a combination of morphine 1 μg and parox-
etine 100 μg was significantly decreased from 19.2  ±  0.5 sec to 
8.1 ± 0.9 sec and 9.9 ± 0.9 sec by naloxone and methysergide, 
respectively (Table 2). The latency of cold allodynia for a com-
bination of morphine 1 μg and citalopram 100 μg was signifi-
cantly decreased from 17.0 ± 0.8 sec to 8.4 ± 0.8 sec and 10.6 ±  
1.0 sec by naloxone and methysergide, respectively (Table 3). 
The threshold of mechanical allodynia for a combination of mor-
phine 1 μg and paroxetine 100 μg was significantly decreased 
from 18.4 ± 0.7 sec to 9.9 ± 0.9 sec and 11.2 ± 1.0 sec by nalox-
one and methysergide, respectively (Table 3). The antinocicep-
tive effects of drug combinations (morphine 0.3 μg and citalo-
pram 100 μg or paroxetine 100 μg) were also significantly re-
versed upon pretreatment of naloxone 20 μg or methysergide 
100 μg with similar pattern (data not shown).
  In experiment 4, the threshold of mechanical allodynia for 
morphine 1 μg significantly decreased from 41.3 ± 4.8 g to 29.0 
± 2.9 g upon pretreatment of methysergide (Table 1). The thresh-
old of mechanical allodynia for morphine 0.3 μg also signifi-
cantly decreased upon pretreatment of methysergide (data not 
shown). The threshold of mechanical allodynia for paroxetine 
decreased significantly from 30.5 ± 2.7 g to 24.2 ± 2.8 g upon 
pretreatment of naloxone (Table 1). The latency of thermal hy-
peralgesia for morphine 1 μg significantly decreased from 12.1 ±  
1.1 g to 6.6 ± 1.0 g upon pretreatment of methysergide (Table 2). 
The threshold of mechanical allodynia for morphine 0.3 μg also 
significantly decreased upon pretreatment of methysergide 
(data not shown). The latency of thermal hyperalgesia for cital-
opram decreased significantly from 5.6 ± 1.2 g to 4.2 ± 0.3 g 
upon pretreatment of naloxone. The latency of thermal hyper-
algesia for paroxetine decreased significantly from 7.2 ± 0.5 g to 
5.7 ± 0.5 g upon pretreatment of naloxone (Table 2). The laten-
cy of cold allodynia for morphine 1 μg significantly decreased 
from 13.2 ± 1.1 g to 8.7 ± 0.9 g upon pretreatment of methyser-
gide (Table 3). The threshold of mechanical allodynia for mor-
phine 0.3 μg also significantly decreased upon pretreatment of 
methysergide (data not shown). The latency of cold allodynia for 
paroxetine decreased significantly from 8.8 ± 0.7 g to 6.8 ± 0.6 g 
upon pretreatment of naloxone (Table 3).
  Intrathecally administered naloxone 20 μg or methysergide 
100 μg alone did not produce any significant effect (data not 
shown). We observed no significant change in rotarod perfor-
mance time when morphine, citalopram, paroxetine, morphine 
plus citalopram, or morphine plus paroxetine were given (data 
not shown). 
DISCUSSION
The present study demonstrated that intrathecal administra-
tion of morphine and SSRIs (citalopram and paroxetine) medi-
ated dose-dependent antiallodynic and antihyperalgesic effects 
in a peripheral rat inflammation model. The antiallodynic and 
antihyperalgesic effects of morphine were potentiated by co-
administration of SSRIs. However, the effects were reversed by 
naloxone and methysergide.
  To the best of our knowledge, this study is the first to examine 
the effects of intrathecally administered morphine, either alone 
or in combinations with SSRIs (citalopram and paroxetine), on 
peripheral inflammation in rats, induced by intraplantar injec-
tion of CFA. Initially, we expected that reports featuring our ex-
perimental parameters (CFA-induced peripheral inflammatory 
pain, intrathecal morphine and SSRI administration, measure-
ment of mechanical allodynia using von Frey filaments, and 
measurement of cold allodynia with cold water) would be avail-
able. Surprisingly, we could not find such reports. Therefore, this 
study is also the first to examine the mechanical and cold-in-
duced antiallodynic effects of intrathecally administered mor-
phine in the CFA-induced rat peripheral inflammatory pain 
model.
  Citalopram and paroxetine selectively inhibit 5-HT reuptake. 
Although no report on the antiallodynic and antihyperalgesic 
effects of citalopram and paroxetine on inflammatory pain has 
appeared, some studies of drug effects in other pain models 
have been performed. In the formalin test, intraperitoneally ad-
Table 3. Time course of cold antiallodynic effects after intrathecal injection of mor-
phine, citalopram, paroxetine, and combinations
Group Baseline 15 min 30 min 45 min 60 min
Control 5.5 ± 0.8 5.5 ± 0.6 5.0 ± 0.6 5.3 ± 0.7 4.9 ± 0.8
C 5.8 ± 0.6 6.4 ± 0.9 5.8 ± 1.0 5.3 ± 0.4 5.6 ± 0.7
P 5.8 ± 0.6 8.8 ± 0.7 7.8 ± 0.7 6.4 ± 0.5 6.0 ± 0.7
m 5.4 ± 0.7 8.9 ± 0.8 7.1 ± 0.6 5.9 ± 1.0 5.2 ± 0.8
mC 5.5 ± 0.6 10.6 ± 1.1* 9.7 ± 1.2* 8.8 ± 0.7* 6.8 ± 0.7
mP 5.6 ± 0.5 12.7 ± 0.7* 11.8 ± 0.8* 9.9 ± 0.6* 9.0 ± 1.2*
M 5.9 ± 0.6 13.2 ± 1.1 10.7 ± 1.3 10.8 ± 1.0 9.1 ± 0.7
MC 5.7 ± 0.7 17.0 ± 0.8
† 15.8 ± 1.6
† 13.2 ± 1.0
† 11.2 ± 0.9
MP 5.7 ± 0.4 18.4 ± 0.7
† 17.6 ± 0.7
† 15.9 ± 0.9
† 13.3 ± 0.9
†
NMC 5.6 ± 0.7 8.4 ± 0.8
‡ 7.6 ± 0.6
‡ 6.2 ± 0.9
‡ 5.8 ± 0.8
‡
TMC 5.6 ± 0.7 10.6 ± 1.0
‡ 9.0 ± 1.2
‡ 9.7 ± 1.2
‡ 8.1 ± 0.7
‡
NMP 5.4 ± 0.5 9.9 ± 0.9
§ 8.2 ± 0.9
§ 7.8 ± 1.0
§ 6.1 ± 0.7
§
TMP 5.9 ± 0.8 11.2 ± 1.0
§ 9.5 ± 1.2
§ 8.2 ± 1.8
§ 7.1 ± 0.7
§
TM 6.0 ± 0.6 8.7 ± 0.9
† 7.7 ± 1.0
† 6.3 ± 0.7
† 6.8 ± 0.8
†
NC 5.2 ± 0.4 5.3 ± 0.5
II 5.4 ± 0.6 5.5 ± 0.5 5.3 ± 0.4
NP 5.4 ± 0.6 6.8 ± 0.6
¶ 6.3 ± 0.4
¶ 5.4 ± 0.4
¶ 5.5 ± 0.4
Data are means ± SDs from eight rats per group. C, citalopram 100 µg; P, paroxetine 
100 µg; m, morphine 0.3 µg; M, morphine 1 µg; T, methysergide 100 µg pretreatment; 
N, naloxone 20 µg pretreatment; mC, mP, MC, MP, TM, NC, and NP, the antiallodynic 
interaction of both drugs; NMC and NMP, pretreatment of naloxon 20 µg before co-
administration of both drugs; TMC and TMP, pretreatment of methysergide 100 µg be-
fore co-administration of both drugs. * < 0.05 vs m; 
† < 0.05 vs M; 
‡ < 0.05 vs MC; 
§ < 0.05 vs MP; 
ll < 0.05 vs C; 
¶ < 0.05 vs P.Lee B-S, et al.  •  Interaction of Morphine and SSRIs
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ministered citalopram (20 mg/kg) produced a partial antinoci-
ceptive effect (a 47.0% reduction) (15). Although intrathecally 
administered citalopram (144 μg) yielded an thermal antihy-
peralgesic effect, intrathecal co-administration of morphine 
with citalopram did not change either the intensity or duration 
of morphine antihyperalgesia (16). Citalopram has been shown 
to be less active in patients with diabetic neuropathy (17, 18).
  Paroxetine is the most potent SSRI (19, 20). In clinical prac-
tice, paroxetine is used for treatment of depressive disorders 
and as an adjuvant drug to alleviate chronic pain (19, 21). Obata 
et al. (22) reported that no antiallodynic effect was produced by 
intrathecal administration of paroxetine (10-100 μg) in the spi-
nal nerve ligation model of Wistar rats and suggested that si-
multaneous inhibition of serotonin and noradrenaline reup-
take in the spinal cord is essential to mediate such an effect. In 
addition, the weak affinity of paroxetine for muscarinic recep-
tors might explain why the drug did not yield an antiallodynic 
effect in the spinal cord. However, on the other hand, Nagata et 
al. (23) reported that intrathecally administered paroxetine (3 
nM, ≈ 1.4 μg; and 10 nM, ≈ 4.5 μg) produced striking antiallo-
dynic effects in the spinal nerve ligation model of Wistar rats. 
The cited authors also suggested that the antiallodynic effect of 
paroxetine was independent of the spinal 5-HT system and was 
mediated at least in part via inhibition of P2X4 receptors. Parox-
etine has been reported to be effective in treatment of diabetic 
neuropathy (24). In the rat model of chronic constriction inju-
ry-induced neuropathic pain, intrathecally administered par-
oxetine (from 10
-3 M ≈ 400 μg to 10
-6 M ≈ 0.4 μg) elicited little 
antiallodynic effect (25). On the other hand, intrathecal admin-
istration of paroxetine (10
-3 M ≈ 400 μg) had an antiallodynic ef-
fect in rats with streptozotocin-induced diabetes (25).
  The possible analgesic effects of citalopram and paroxetine 
remain controversial, especially in terms of dosage. In the pres-
ent study, citalopram alone yielded no antiallodynic or antihy-
peralgesic effect at any dose (10-100 μg) tested. Paroxetine pro-
duced no antiallodynic or antihyperalgesic effect at low doses 
(10-30 μg, data not shown). However, at a higher dose (100 μg), 
paroxetine administration caused partial antiallodynic or anti-
hyperalgesic effects (16.3%-33.7% elevation). 
  Although the exact mechanisms of the antiallodynic and an-
tihyperalgesic effects of citalopram and paroxetine remain un-
clear, we suggest that neuropathic pain and neuroinflamma-
tion are caused by similar mechanisms and that inhibition of 
serotonin reuptake in the spinal cord plays a major role in me-
diating antiallodynic and antihyperalgesic effects in the inflam-
matory pain state. In the present study, intrathecally adminis-
tered morphine alone (0.3 and 1 μg) produced antiallodynic or 
antihyperalgesic effects (24.0%-71.9% elevation). In addition, 
the antiallodynic and antihyperalgesic effects of morphine were 
significantly increased when the drug was combined with cital-
opram or paroxetine (35.2%-95.1% elevation). These effects 
were reversed by naloxone and methysergide. The antiallodyn-
ic and antihyperalgesic effects of citalopram and paroxetine 
were also reversed by naloxone and methysergide. These data 
are consistent with a report that the antinociceptive effect of 
paroxetine was reversed by subcutaneously administered nal-
oxone (0.5 mg/kg) (26). Therefore, we suggest that the mu opi-
oid receptor and serotonin receptors are involved in produc-
tion of the antiallodynic and antihyperalgesic effect of morphine, 
citalopram, paroxetine, and combinations thereof, in animals 
experiencing inflammatory pain. 
  It has been reported that morphine and serotonin can in-
crease the extent of endogenous adenosine release from spinal 
cord synaptosomes in vitro (27). The effect of intrathecally ad-
ministered morphine is enhanced by adenosine and adenosine 
A1 receptor agonists (28, 29). Therefore, it is possible that the 
morphine and adenosine receptors interact to increase the an-
tiallodynic and antihyperalgesic effects of combinations of mor-
phine and citalopram/paroxetine.
  In the present study, the time courses of mechanical antial-
lodynic, thermal antihyperalgesic, and cold antiallodynic effects 
of morphine, citalopram, paroxetine, and combinations there-
of, showed similar patterns. Generally the effects peaked 15 min 
after intrathecal injection, and next gradually decreased over 
time. It has been reported that nerve injury-induced thermal 
and tactile hypersensitivity differ mechanistically (30). Nerve 
injury-induced thermal hypersensitivity is thought to be medi-
ated by abnormal activity of C fibers, whereas tactile hypersen-
sitivity is mediated by Aβ fibers (31). In the present study, we 
observed differences in the antiallodynic and antihyperalgesic 
effects of neuropathic and inflammatory pain. This suggests 
that different mechanisms induce the two types of pain.
  In conclusion, it is suggested that the mu opioid receptor and 
serotonin receptors may play major roles in production of the 
antiallodynic and antihyperalgesic effects of citalopram, parox-
etine, morphine, and combinations thereof, in animals experi-
encing inflammatory pain. Intrathecal co-administration of 
morphine and citalopram/paroxetine might be useful in treat-
ment of peripheral inflammatory pain itself or assorted neuro-
pathic pain combined with inflammation. Further work is nec-
essary to determine the mechanism of interaction between mor-
phine and SSRIs at the spinal or supraspinal level.
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